GlassScriptPhysician profile
Yoram C Padeh
NPI 1740266311
$51,545.20
in general payments reported to CMS, 2019-2025
33 companies · $3,306 in 2025
The $3,306 reported for 2025 was more than what 78% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,565 · 2020: $13K · 2021: $5,807 · 2022: $10K · 2023: $9,282 · 2024: $4,182 · 2025: $3,306.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,500 · Food and Beverage: $8,070 · Education: $130 · Travel and Lodging: $69.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,500.00 |
| Food and Beverage | $8,070.47 |
| Education | $129.80 |
| Travel and Lodging | $69.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharming Healthcare, INC. | $33,753.54 | 2019-2025 | Ruconest |
| Takeda Pharmaceuticals U.S.A., INC. | $4,075.95 | 2020-2025 | Takhzyro, Cuvitru, Hyqvia |
| Astrazeneca Pharmaceuticals LP | $3,722.31 | 2019-2025 | Airsupra, Tezspire, Fasenra |
| Regeneron Healthcare Solutions, INC. | $1,870.62 | 2019-2025 | Dupixent |
| Glaxosmithkline, LLC. | $1,849.59 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $1,482.63 | 2019-2025 | |
| Csl Behring | $850.46 | 2019-2025 | Haegarda, Andembry, Hizentra |
| Optinose US, INC. | $612.37 | 2019-2025 | |
| Galderma Laboratories, L.P. | $443.60 | 2025 | Nemluvio |
| Genentech USA, INC. | $317.06 | 2019-2023 | Xolair |
| Shire North American Group INC | $282.76 | 2019 | |
| Biocryst US Sales Co., LLC | $217.50 | 2022-2025 | Orladeyo |
| Pfizer INC. | $212.69 | 2020-2024 | |
| Kaleo, INC. | $207.43 | 2019-2024 | Auvi-Q |
| Alk-Abello, INC | $188.42 | 2019-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $181.25 | 2019-2025 | |
| Eyevance Pharmaceuticals LLC | $170.15 | 2021 | |
| Abbvie INC. | $148.85 | 2021-2025 | |
| Amgen INC. | $141.22 | 2021-2024 | Tezspire |
| Aimmune Therapeutics, INC. | $107.19 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $94.55 | 2019-2021 | |
| Cycle Pharmaceuticals INC | $91.16 | 2024-2025 | Sajazir |
| Octapharma USA, INC. | $80.42 | 2019-2024 | Cutaquig |
| Ionis Pharmaceuticals, INC. | $78.98 | 2025 | Dawnzera |
| Verona Pharma, INC. | $78.71 | 2025 | Ohtuvayre |
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.81 | 2019-2021 | |
| Lilly USA, LLC | $44.42 | 2025 | Ebglyss |
| Ars Pharmaceuticals Operations, INC. | $32.88 | 2025 | Neffy |
| Grifols USA, LLC | $32.66 | 2021-2024 | Xembify |
| Greer Laboratories, INC. | $30.68 | 2025 | Oralair |
| Azurity Pharmaceuticals, INC. | $30.26 | 2025 | Alvesco |
| Blueprint Medicines Corporation | $23.30 | 2025 | Ayvakit |
| Organon LLC | $20.78 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yoram Padeh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.